Compare CHCT & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHCT | VSTM |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 489.7M | 470.7M |
| IPO Year | 2015 | 2011 |
| Metric | CHCT | VSTM |
|---|---|---|
| Price | $17.83 | $5.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $18.00 | $16.50 |
| AVG Volume (30 Days) | 186.8K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.07% | N/A |
| EPS Growth | ★ 134.78 | 17.49 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $121,195,000.00 | $30,914,000.00 |
| Revenue This Year | $9.06 | $282.64 |
| Revenue Next Year | $8.61 | $72.25 |
| P/E Ratio | $252.00 | ★ N/A |
| Revenue Growth | 4.67 | ★ 209.14 |
| 52 Week Low | $13.23 | $4.01 |
| 52 Week High | $18.22 | $11.25 |
| Indicator | CHCT | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 60.33 | 48.11 |
| Support Level | $16.38 | $5.38 |
| Resistance Level | $18.22 | $6.79 |
| Average True Range (ATR) | 0.50 | 0.36 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 78.49 | 37.08 |
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems, or other healthcare service providers in non-urban markets. The company derives the majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.